Skip to content


PARP inhibitors in cancer – shifting the paradigm to frontline treatment

The last decade has seen major advances in oncology therapy with the addition of PARP inhibitors, with significant updated data on their usage across a range of cancers in the last 12 months Tubo-ovarian cancer The last 12 months has continued to see PARP inhibitors lead the field as regards therapeutic advancement in advanced tubo-ovarian…

Read More

The 2019 European Society for Medical Oncology (ESMO) Asia Congress, Singapore

First China-manufactured trastuzumab biosimilar HLX02 global phase 3 trial met primary endpoint in breast cancer outcomes The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase 3 study reported at…

Read More

Breast cancer in Ireland

Priscilla Lynch reports on the latest data on breast cancer incidence, treatment, and outcomes in Ireland The National Cancer Registry of Ireland (NCRI) recently released a new trends report for breast cancer (Cancer Trends: Breast cancer 1994-2016). This report shows that the rate of new cases of invasive breast cancer in Irish women has stabilised…

Read More

Gathering together to tackle cancer

Sandra Ryan provides an overview of this year’s Gathering around Cancer Conference, which was held in Dublin recently This year’s Gathering around Cancer event — now in its seventh year — in the Croke Park Convention Centre brought together hundreds of cancer specialists from both Ireland and the US to hear the latest evidence-based updates…

Read More

All together now

Next month, the seventh Gathering Around Cancer conference takes place in Croke Park, Dublin. David Lynch talks to two organisers about what delegates can expect Since it began in 2013, the Gathering Around Cancer event has developed and changed significantly, two of the principal organisers have told the Medical Independent (MI). Now in its seventh…

Read More

ASCO Annual Meeting 2019, Chicago, IL

Priscilla Lynch presents a round-up of the most important studies presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Pembrolizumab increases survival rate for certain people with advanced non-small cell lung cancer – KEYNOTE-001 Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab was safe and effective and substantially…

Read More

No benefit from pazopanib in advanced renal cell carcinoma after metastasectomy

No improvement in disease-free survival (DFS) with adjuvant pazopanib (a VEGF tyrosine kinase inhibitor) was observed for patients with no evidence of disease following metastasectomy for renal cell carcinoma (RCC) when compared with placebo, according to results of a phase 3 trial presented at the 2019 ASCO Annual Meeting. Although effective targeted therapy has become…

Read More

Immunotherapy in metastatic or recurrent cervical cancer

Dr Dearbhaile Collins outlines the latest trial data on immunotherapies for cervical cancer The National Cancer Registry Ireland records 262 new cases of invasive cervical cancer in Ireland each year. This is predominantly a disease of younger women, with over 47 per cent of patients under the age of 45 years old at diagnosis. Squamous…

Read More

The introduction of robotic prostate surgery at Galway University Hospitals

The introduction of robotic surgery in GUH is a major benefit for prostate patients, writes Mr Paddy O’Malley In July of last year the first robotic-assisted radical prostatectomy was performed on a patient at Galway University Hospitals (GUH) by Mr Paddy O’Malley, Consultant Urologist and specialist in robotic surgery, GUH. This was a cumulative effort…

Read More
Scroll To Top